SEARCH

SEARCH BY CITATION

References

  • 1
    Silverberg SJ, Bilezikian JP. Clinical presentation of primary hyperparathyroidism in the United States. In: MarcusR, LevineMA, eds. The Parathyroids. New York, USA: Academic Press, 2001; 34960.
  • 2
    Heath H, Hodgson SF, Kennedy MA. Primary hyperparathyroidism: incidence, morbidity, and economic impact in a community. N Engl J Med 1980; 302: 18993.
  • 3
    Ringe JD. Reversible hypertension in primary hyperparathyroidism: pre- and postoperative blood pressure in 75 cases. Klin Wochenschr 1984; 62: 4659.
  • 4
    Broulik PD, Horky K, Pacovsky V. Blood pressure in patients with primary hyperparathyroidism before and after parathyroidectomy. Exp Clin Endocrinol 1985; 86: 34652.
  • 5
    Rapado A. Arterial hypertension and primary hyperparathyroidism. Am J Nephrol 1986; 6(Suppl. 1): 4950.
  • 6
    Bilezikian JP, Aurbach GD, Connor TB et al. Pseudogout following parathyroidectomy. Lancet 1973; 1: 4457.
  • 7
    Geelhoed GW, Kelly TR. Pseudogout as a clue and complication in primary hyperparathyroidism. Surgery 1989; 106: 103641.
  • 8
    Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 565871.
  • 9
    Heppner C, Kester MB, Agarwal SK et al. Somatic mutations of the MEN1 gene in parathyroid tumours. Nat Gen 1997; 16: 3758.
  • 10
    Simonds WF, James-Newton LA, Agarwal SK et al. Familial isolated hyperparathyroidism: clinical and genetic characteristics of thirty-six kindreds. Medicine (Baltimore) 2002; 81: 126.
  • 11
    Marx SJ, Simonds SF, Agarwal SK et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res 2002; 17(Suppl. 2): N3743.
  • 12
    Lepage R, Roy L, Brossard JH et al. A non(1–84)-circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998; 44: 8059.
  • 13
    John MR, Goodman WG, Gao P, Cantor T, Salusky IB, Jueppiner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurement in renal failure. J Clin Endocrinol Metab 1999; 84: 428790.
  • 14
    Gao, P, Scheibel S, D'Amour P et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1–84. Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001; 16: 60514.
  • 15
    Silverberg SJ, Brown I, LoGerfo P, Gao P, Cantor T, Bilezikian JP. Clinical utility of an immunoradiometric assay for whole PTH (1–84) in primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 472530.
  • 16
    Silverberg SJ, Bilezikian JP. ‘Incipient’ primary hyperparathyroidism: a ‘forme fruste’ of an old disease. J Clin Endocrinol Metab 2003; 88: 534852.
  • 17
    Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 1988; 67: 12948.
  • 18
    Silverberg SJ, Gartenberg F, Jacobs TP et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 1995; 80: 723238.
  • 19
    Silverberg SJ, Shane E, DeLaCruz L et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989; 4: 28391.
  • 20
    Bilezikian JP, Silverberg SJ, Shane E et al. Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 1991; 6(Suppl. I): 5859.
  • 21
    Silverberg SJ, Locker FG, Bilezikian JP. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 400712.
  • 22
    Parisien M, Silverberg SJ, Shane E et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 1990; 70: 9308.
  • 23
    Parfitt AM. Surface specific bone remodeling in health and disease. In: KleerekoperM, ed. Clinical Disorders of Bone and Mineral Metabolism. New York, USA: Mary Ann Liebert, 1989; 714.
  • 24
    Parisien M, Cosman F, Mellish RWE et al. Bone structure in postmenopausal hyperparathyroid, osteoporotic and normal women. J Bone Miner Res 1995; 10: 13939.
  • 25
    Parisien M, Mellish RWE, Silverberg SJ et al. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular and strut analysis. J Bone Miner Res 1992; 7: 91320.
  • 26
    Dempster DW, Parisien M, Silverberg SJ et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 1999; 84: 15626.
  • 27
    Dauphine RT, Riggs BL, Scholz DA. Back pain and vertebral crush fractures: an unemphasized mode of presentation for primary hyperparathyroidism. Ann Intern Med 1975; 83: 3657.
  • 28
    Kochesberger G, Buckley NJ, Leight GS et al. What is the clinical significance of bone loss in primary hyperparathyroidism. Arch Intern Med 1987; 147: 19513.
  • 29
    Wilson RJ, Rao S, Ellis B et al. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988; 109: 95962.
  • 30
    Larsson K, Ljunghall S, Krusemo UB et al. The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years. J Intern Med 1993; 234: 58593.
  • 31
    Kenny AM, MacGillivray DC, Pilbeam CC et al. Fracture incidence in postmenopausal women with primary hyperparathyroidism. Surgery 1995; 118: 10914.
  • 32
    Khosla S, Melton LJ, Wermers RA et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 1999; 14: 17007.
  • 33
    Adami S, Braga V, Squaranti R, Rossini M, Gatti D, Zamberlan N. Bone measurements in asymptomatic primary hyperparathyroidism. Bone 1998; 22: 56570.
  • 34
    Parfitt AM. Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002; 17: 17413.
  • 35
    Bilezikian JP. Bone strength in primary hyperparathyroidism. Osteoporos Int 2003; 14(Suppl. 5): 51137.
  • 36
    Mallette LE, Bilezikian JP, Heath DA, Aurbach GD. Hyperparathyroidism: a review of 52 cases. Medicine (Baltimore) 1974; 53: 12747.
  • 37
    Broadus AE, Horst RL, Lang R et al. The importance of circulating 1,25(OH)2D in the pathogenesis of hypercalciuria and renal stone formation in primary hyperparathyroidism. N Engl J Med 1980; 302: 4216.
  • 38
    Silverberg SJ, Shane E, Jacobs TP et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism, 1985–1990. Am J Med 1990; 89: 32734.
  • 39
    Klugman VA, Favus M, Pak CYC. Nephrolithiasis in primary hyperparathyroidism. In: BilezikianJP, ed. The Parathyroids: Basic and Clinical Concepts. New York, USA: Academic Press, 2001; 43750.
  • 40
    Pak CYC, Nicar MJ, Peterson R et al. Lack of unique pathophysiologic background for nephrolithiaisis in primary hyperparathyroidism. J Clin Endocrinol Metab 1981; 53: 53642.
  • 41
    Silverberg SJ. Non-classical target organs in primary hyperparathyroidism. J Bone Miner Res 2003; 17(Suppl. 2): N11725.
  • 42
    Aurbach GD, Mallette LE, Patten BM et al. Hyperparathyroidism: recent studies. Ann Intern Med 1973; 79: 56681.
  • 43
    Patten BM, Bilezikian JP, Mallette LE et al. The neuromuscular disease of hyperparathyroidism. Ann Intern Med 1974; 80: 18294.
  • 44
    Turken SA, Cafferty M, Silverberg SJ et al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med 1989; 87: 5537.
  • 45
    Joborn C, Hetta J, Johansson H et al. Psychiatric morbidity in primary hyperparathyroidism. World J Surg 1998; 2: 47681.
  • 46
    Solomon BL, Schaaf M, Smallridge RC. Psychologic symptoms before and after parathyroid surgery. Am J Med 1994; 96: 1016.
  • 47
    Clark OH. Presidential address: ‘Asymptomatic’ primary hyperparathyroidism: is parathyroidectomy indicated? Surgery 1994; 116: 947.
  • 48
    Pasieka JL, Parsons L. Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism. World J Surg 1998; 22: 5139.
  • 49
    Burney RE, Jones KR, Christy B, Thompson NW. Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels. Surgery 1999; 125: 60814.
  • 50
    Talpos GB, Bone HG, Kleerekoper M et al. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery 2000; 128: 101320.
  • 51
    Brown GG, Preisman RC, Kleerekoper MD. Neurobehavioral symptoms in mild hyperparathyroidism: related to hypercalcemia but not improved by parathyroidectomy. Henry Ford Med J 1987; 35: 2115.
  • 52
    Cogan MG, Covey CM, Arieff AI, Clark OH. Central nervous system manifestations of hyperparathyroidism. Am J Med 1978; 65: 96370.
  • 53
    Lafferty FW. Primary hyperparathyroidism: changing clinical spectrum, prevalence of hypertension, and discriminant analysis of laboratory tests. Arch Intern Med 1981; 141: 17616.
  • 54
    Symons C, Fortune F, Greenbaum RA, Dandona P. Cardiac hypertrophy, hypertrophic cardiomyopathy and hyperparathyroidism – an association. Br Heart J 1985; 54: 53942.
  • 55
    Diamond TH, Kawalski DL, van der Merwe TL, Myburgh DP. Hypercalcemia due to parathyroid adenoma and hypertrophic cardiomyopathy. S Afr Med J 1987; 71: 4489.
  • 56
    Stefenelli T, Mayr H, Berger-Klein J, Globits S, Wolosczuk W, Niederle B. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med 1993; 95: 197202.
  • 57
    Niederle B, Stefenelli T, Glogar D, Woloszczuk W, Roka R, Mayr H. Cardiac calcific deposits in patients with primary hyperparathyroidism: preliminary results of a prospective echocardiographic study. Surgery 1990; 108: 10526.
  • 58
    Barletta G, De Feo ML, Del Bene R et al. Cardiovascular effects of parathyroid hormone: a study in healthy subjects and normotensive patients with mild hyperparathyroidism. J Clin Endocrinol Metab 2000; 85: 181521.
  • 59
    Nilsson IL, Aberg J, Rastad J, Lind L. Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery 1999; 126: 104955.
  • 60
    Neunteufl T, Katzenschlager R, Abela C et al. Impairment of endothelium-independent vasodilation in patients with hypercalcemia. Cardiovasc Res 1998; 40: 396401.
  • 61
    Smith JC, Page MD, Wheeler MH, Cockroft JR, Scanlon MF, Davies JS. Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85: 35159.
  • 62
    Rubin MR, Bilezikian JP, Silverberg SJ. Vascular stiffness is increased in patients with primary hyperparathyroidism. J Bone Miner Res 2002; 17: S381.
  • 63
    Jensen RT. Management of Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type1. J Intern Med 1998; 243: 47788.
  • 64
    Marx SJ, MEN type 1. In: BilezikianJP, ed. The Parathyroids, 2nd edn. San Diego, USA: Academic Press, 2001; 53584.
  • 65
    Norton JA, Cornelius MJ, Doppman JL, Maton PN, Gardner JD, Jensen RT. Effect of parathyroidectomy in patients with Zollinger-Ellison syndrome and MEN1. A prospective study. Surgery 1987; 102: 95866.
  • 66
    Brandi ML, Gagel RF, Angeli A. Consensus guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 565871.
  • 67
    Bess MA, Edis AJ, van Heerden JA. Hyperparathyroidism and pancreatitis. Chance or a causal association? JAMA 1980; 243: 2467.
  • 68
    Harinarayan DV, Gupta N, Kochupillai N. Vitamin D status in primary hyperparathyroidism in India. Clin Endocrinol 1995; 43: 3518.
  • 69
    Meng XW, Xing XP, Liu SQ. The diagnosis of primary hyperparathyroidism – analysis of 134 cases. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1994; 16: 139.
  • 70
    Luong KVQ, Nguyen LTH. Coexisting hyperthyroidism and hyperparathyroidism with vitamin D deficient osteomalacia in a Vietnamese immigrant. Endocr Pract 1996; 2: 2504.
  • 71
    Lumb GA, Stanbury SW. Parathyroid function in vitamin D deficiency in primary hyperparathyroidism. Am J Med 1974; 54: 8339.
  • 72
    Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. Vitamin D deficiency in primary hyperparathyroidism. Am J Med 109; 107: 5617.
  • 73
    Palmer M, Adami HO, Bergstrom R et al. Mortality after surgery for primary hyperparathyroidism. A follow-up of 441 patients operated on from 1956 to 1979. Surgery 1987; 102: 17.
  • 74
    Palmer M, Adami HO, Bergstrom G et al. Survival and renal function in untreated hypercalcemia. Lancet 1987; I: 5962.
  • 75
    Wermers RA, Khosla S, Atkinson EJ et al. Survival after the diagnosis of hyperparathyroidism. Am J Med 1998; 104: 11522.
  • 76
    National Institutes of Health. Consensus development conference statement on primary hyperparathyroidism. J Bone Miner Res 1991; 6: s9s13.
  • 77
    Bilezikian JP, Potts JT Jr, El-Hajj Fuleihan G et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 2002; 17(Suppl. 2): N2N11. J Clin Endocrinol Metab 2002; 87: 5353 – 61.
  • 78
    Burgess JR, David R, Greenaway TM, Parameswaran V, Sheperd JJ. Osteoporosis in multiple endocrine neoplasia type 1. Arch Surg 1999; 134: 111923.
  • 79
    Sato M, Miyauchi A, Takahara J. Clinical aspects of hyperparathyroidism in Japanese multiple endocrine neoplasia type 1. Biomed Pharmacother 2000; 54: 869.
  • 80
    Colli E, Fratini G, Tonelli F, Brandi ML. Forearm autograft recurrence after 37 consecutive total parathyroidectomies for primary hyperparathyroidism in MEN1 syndrome. J Intern Med 2004; 255: 715.
  • 81
    Marx SJ. Multiple endocrine neoplasia type 1. In: ScriverCR, BeaudetAL, SlyWS, ValleD, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, USA: McGraw-Hill, 2001; 94366.
  • 82
    Norton KS, Zibari GB, Johnson LW. Use of the Sestamibi scan to identify hyperplastic parathyroid tissue in the forearm of a patient with MEN1 syndrome. J La State Med Soc 2001; 153: 6057.
  • 83
    Kivlen MH, Bartlett DL, Ributti SK et al. Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery 2001; 130: 9918.
  • 84
    Deaconson TF, Wilson SD, Lemann J. The effect of parathyroidectomy on the recurrence of nephrolithiasis. Surgery 1987; 215: 24151.
  • 85
    Bilezikian JP, Silverberg SJ. Management of asymptomatic primary hyperparathyroidism. N Engl J Med 2004; 350: 174651.
  • 86
    Kulak CAM, Bandeira C, Voss D et al. Marked improvement in bone mass after parathyroidectomy in osteititis fibrosa cystica. J Clin Endocrinol Metab 1998; 83: 7325.
  • 87
    Tritos NA, Hartzband P. Rapid improvement of osteoporosis following parathyroidectomy in a premenopausal woman with acute primary hyperparathyroidism. Arch Intern Med 1999; 139: 1498.
  • 88
    DiGregorio S. Hiperparatiroidismo primario: dramatico incremento de la masa ostea post paratiroidectomia. Diagn Osteol 1999; 1: 115.
  • 89
    Silverberg SJ, Shane E, Jacobs TP et al. Primary hyperparathyroidism: 10-year course with or without parathyroid surgery. N Engl J Med 1999; 341: 124955.
  • 90
    Parfitt AM, Rao DS, Kleerekoper M. Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and considerations bearing on the need for surgical intervention. J Bone Miner Res 1991; 6(Suppl. 2): S97S101.
  • 91
    Dawson-Hughes B, Stern DT, Shipp CC, Rasmussen HM. Effect of lowering dietary calcium intake on fractional whole body calcium retention. J Clin Endocrinol Metab 1998; 67: 628.
  • 92
    Barger-Lux MJ, Heaney RP. Effects of calcium restriction on metabolic characteristics of premenopausal women. J Clin Endocrinol Metab 1993; 76: 1037.
  • 93
    Calvo MS, Kumar R, Heath H. Persistently elevated parathyroid hormone secretion and action in young women after four weeks of ingesting high phosphorus, low calcium diets. J Clin Endocrinol Metab 1990; 70: 133440.
  • 94
    Insogna KL, Mitnick ME, Stewart AF et al. Sensitivity of the parathyroid hormone-1, 25-dihydroxyvitamin D axis to variations in calcium intake in patients with primary hyperparathyroidism. N Engl J Med 1985; 313: 112630.
  • 95
    Locker FG, Silverberg SJ, Bilezikian JP. Optimal dietary calcium intake in primary hyperparathyroidism. Am J Med 1997; 102: 54350.
  • 96
    Gallagher JC, Nordin BEC. Treatment with oestrogens of primary hyperparathyroidism in post-menopausal women. Lancet 1972; 1: 5037.
  • 97
    Marcus R, Madvig P, Crim M et al. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 1984; 100: 63340.
  • 98
    Selby PL, Peacock M. Ethinyl estradiol and norethinedrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med 1986; 314: 14815.
  • 99
    Grey AB, Stapleton JP, Evans MC et al. Effect of hormone replacement therapy on BMD in post-menopausal women with primary hyperparathyroidism. Ann Intern Med 1996; 125: 3608.
  • 100
    Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. J Am Med Assoc 2002; 228: 32133.
  • 101
    Marcus R. The role of estrogens and related compounds in the management of primary hyperparathyroidism. J Bone Miner Res 2002; 17(Suppl. 2): N1469.
  • 102
    Rubin MA, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 11748.
  • 103
    Kaplan RA, Geho WB, Poindexter C et al. Metabolic effects of diphosphonate in primary hyperparathyroidism. J Clin Pharmacol 1997; 17: 4109.
  • 104
    Shane E, Baquiran DC, Bilezikian JP. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Intern Med 1981; 95: 237.
  • 105
    Hassani S, Braunstein GD, Seibel MJ et al. Alendronate therapy of primary hyperparathyroidism. Endocrinologist 2001; 11: 45964.
  • 106
    Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001; 16: 1139.
  • 107
    Chow CC, Chan WB, Li JKY et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 5817.
  • 108
    Kahn AA, Bilezikiam JP, Kung AWC et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 331925.
  • 109
    Reasner CA, Stone MD, Hosking DJ et al. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 1993; 77: 106771.
  • 110
    Brown EM, Pollak M, Seidman CE et al. Calcium ion sensing cell surface receptors. N Engl J Med 1995; 333: 23440.
  • 111
    Silverberg SJ, Marriott TB, Bone HG III et al. Short term inhibition of parathyroid hormone secretion by a calcium receptor agonist in primary hyperparathyroidism. N Engl J Med 1997; 307: 150610.
  • 112
    Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic AMG 073 normalizes serum calcium in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 56449.
  • 113
    Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med 1954; 16: 36371.